PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
31058459-0	2019	Functional characterization of 27 CYP3A4 protein variants to metabolize regorafenib in vitro.	regorafenib	72-83	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	34-40	
31058459-4	2019	However, the catalytic characteristics of these 27 CYP3A4 variants on oxidizing regorafenib have not being determined.	regorafenib	80-91	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	51-57	
32034953-2	2020	Regorafenib is metabolized by CYP3A4 in the liver to its active metabolites, M-2 and M-5.	regorafenib	0-11	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	30-36	
31058459-1	2019	AIM: Regorafenib is a tyrosine kinase inhibitor that is mainly metabolized by CYP3A4.	regorafenib	5-16	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	78-84	
31058459-5	2019	The purpose of this study was to investigate the catalytic characteristics of 27 CYP3A4 protein variants on the oxidative metabolism of regorafenib in vitro.	regorafenib	136-147	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	81-87	
31058459-6	2019	METHOD: Wild-type CYP3A4.1 or other variants was incubated with 0.5-20 mumol/L regorafenib for 30 minutes.	regorafenib	79-90	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	18-24	
31058459-2	2019	The genetic polymorphism of CYP3A4 would contribute to differences in metabolism of regorafenib.	regorafenib	84-95	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	28-34	
31058459-9	2019	CONCLUSION: This study is the first to investigate the function of 27 CYP3A4 protein variants on the metabolism of regorafenib in vitro, and it may provide some valuable information for further research in clinic.	regorafenib	115-126	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	70-76	
31293154-6	2019	Besides, we compared cabozantinib with regorafenib in relative clearance to confirm that CYP3A4 has the property of substrate specificity.	regorafenib	39-50	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	89-95	
27500989-5	2016	Clinical history, liver histology and genetic assessment (sequence analysis) of cytochrome P3A4 (CYP3A4) and uridine diphosphate-glucuronosyltransferase 1A9 (UGT1A9) involved in regorafenib metabolization were here reported for patients with severe hepatotoxicity.	regorafenib	178-189	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	80-95	
27500989-5	2016	Clinical history, liver histology and genetic assessment (sequence analysis) of cytochrome P3A4 (CYP3A4) and uridine diphosphate-glucuronosyltransferase 1A9 (UGT1A9) involved in regorafenib metabolization were here reported for patients with severe hepatotoxicity.	regorafenib	178-189	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	97-103	
24405315-12	2014	Regorafenib is mainly metabolized by CYP3A4, and concomitant use of strong inducers/inhibitors of this enzyme should be avoided.	regorafenib	0-11	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	37-43